STARKS ASSOCIATES INC.

Starks Associates Inc. specializes in preclinical research and development for pharmaceutical and therapeutic candidates, with deep expertise in organic synthesis, compound batching, and in vitro/in vivo biological testing support. The firm delivers end-to-end drug development services, including the design and production of novel therapeutic agents for infectious diseases and other clinical applications, bridging chemical synthesis with early-stage pharmacological evaluation. Their technical proficiency spans medicinal chemistry, compound characterization, and preclinical pipeline acceleration, enabling clients to advance candidate molecules through critical development milestones. A key differentiator is their focused execution in non-biotech, small-molecule drug discovery, where precision synthesis and rapid batch acquisition are essential to downstream testing timelines. The company maintains a strong, sustained relationship with the Department of Health and Human Services, consistently supporting its research arms in advancing candidate therapeutics. Their work for HHS centers on synthesizing bioactive compounds, conducting preclinical development activities, and enabling translational research for infectious disease treatments, indicating a trusted, long-term partnership rooted in scientific rigor and regulatory alignment. Starks Associates operates primarily within NAICS 541715 and 541712, focusing on physical and engineering sciences research excluding biotechnology and nanotechnology. This positions them as a niche provider in small-molecule drug discovery, serving government-funded initiatives that require high-purity chemical synthesis and early-stage pharmacological validation. Their market niche lies in supporting the transition from chemical design to biological proof-of-concept, a critical gap in federal biomedical R&D. As a small business structured as a 2L entity based in Buffalo, NY, Starks Associates Inc. operates without federal certifications but maintains a focused, mission-driven presence in the government science and technology market. Their geographic footprint and operational model reflect a lean, high-impact research firm optimized for specialized federal R&D contracts.